This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Chronic progressive external ophthalmoplegia (CPEO) is a mitochondrial cytopathy characterized by bilateral ptosis during adolescence, followed later by limitation of extraocular muscle movement and diplopia.1 The biochemical defect consists of mutations or deletions of mitochondrial DNA genes that encode respiratory chain enzymes involved in adenosine triphosphate (ATP) generation and its subsequent translocation from the mitochondria.1 To date, there is no definitive treatment that reverses or halts the progression of the muscle weakness. Herein, we report improvement in ocular motility in a patient with CPEO following treatment with tetracycline. The retrospective review was approved by the institutional review board.
Case report.
A 47-year-old woman, with bilateral upper eyelid ptosis since childhood, underwent ptosis repair in 1987, at age 28. There was a gradual return of the ptosis over the ensuing years. By age 33, she began experiencing diplopia. She had otherwise enjoyed excellent health. Her family history was significant for six brothers and three sisters with ptosis.
We initially evaluated her in October 1997, at age 38, for diplopia and ptosis. Her visual acuity was 20/20 for both eyes. There was 6- to …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
A novel missense adenine nucleotide translocator-1 gene mutation in a Greek adPEO family
Mitochondrial encephalomyopathies—Fifty years on
Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase γ mutations
A new mtDNA mutation associated with a progressive encephalopathy and cytochrome c oxidase deficiency